Claims for Patent: 8,492,438
✉ Email this page to a colleague
Summary for Patent: 8,492,438
Title: | Treatment skin disorders |
Abstract: | Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia. |
Inventor(s): | Chung; Yih-Lin (Taipei, TW), Pui; Nam-Mew (Taipei, TW), Chang; Wei-Wei (Boston, MA) |
Assignee: | Asan Laboratories Company (Cayman), Limited (Taipei, TW) |
Application Number: | 13/021,063 |
Patent Claims: | 1. A method for treating a skin disorder, comprising administering to a subject in need thereof a composition containing an effective amount of a histone hyperacetylating
agent or a pharmaceutically acceptable salt thereof, and a cosmetically or pharmaceutically acceptable carrier, wherein the skin disorder is selected from the group consisting of rosacea, pityriasis rosea, erythema, rhinophyma, and a rosacea-associated
disorder that is pimple, papule, pustule, or telangiectasia, and the histone hyperacetylating agent is selected from the group consisting of trichostatin A, trichostatin C, oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, chlamydocin,
salicylihydroxamic acid, suberoylanilide hydroxamic acid, azelaic bishydroxamic acid, azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid bishydroxamide, 6-(3-chlorophenylureido) carpoic hydroxamic acid, MW2796, MW2996, sodium butyrate, arginine
butyrate, isovalerate, valerate, 4-phenylbutyrate, propionate, butyramide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, tributyrin, MS-27-275 or a 3'-amino derivative thereof, depudecin, and scriptaid.
2. The method of claim 1, wherein the composition is a topical composition. 3. The method of claim 2, wherein the histone hyperacetylating agent is trichostatin A or trichostatin C. 4. The method of claim 2, wherein the histone hyperacetylating agent is oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, or chlamydocin. 5. The method of claim 2, wherein the histone hyperacetylating agent is salicylihydroxamic acid, suberoylanilide hydroxamic acid, or azelaic bishydroxamic acid. 6. The method of claim 2, wherein the histone hyperacetylating agent is azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid bishydroxamide, 6-(3-chlorophenylureido) carpoic hydroxamic acid, MW2796, or MW2996. 7. The method of claim 2, wherein the histone hyperacetylating agent is sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, propionate, butyramide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, or tributyrin. 8. The method of claim 2, wherein the histone hyperacetylating agent is MS-27-275 or a 3'-amino derivative thereof. 9. The method of claim 2, wherein the histone hyperacetylating agent is depudecin or scriptaid. 10. The method of claim 2, wherein the composition is a cream, an ointment, a gel, a paste, a powder, an aqueous solution, a spray, a suspension, a dispersion, a salve, a lotion, a patch, a suppository, a liposome formulation, a mouth wash, an enema, an eye drop, an ear drop, a microcapsule formulation, or a nanocapsule formulation. 11. The method of claim 1, wherein the method further comprises administering to the subject a second agent that is a cytokine, a cytokine antagonist, an interleukin, an interleukin antagonist, a growth factor, an angiogenic agent, an anti-histamine, an anti-fibrogenic agent, a vasoactive agent, an antibody, a conjugated antibody, an adenosine receptor agonist, a peroxisome proliferating activator receptor agonist, an anticholinergics, a non-steroid anti-inflammation drug, a steroid, an anti-oxidant agent, a vitamin, a leukotriene modifier, a mast cell inhibitor, an anti-IgE antibody, lidocaine, epinephrine, a selective serotonin reuptake inhibitor, a 5-hydroxytryptamine receptor antagonist, an antibiotics, a calcineurin inhibitor, an amino acid, a matrix metalloproteinase inhibitor, a DNA methylation inhibitor, collagenase, clostridium histolyticum, or combinations thereof. 12. The method of claim 11, wherein the composition and the second agent are topically administered simultaneously or separately. 13. The method of claim 1, wherein the skin disorder is rosacea. 14. The method of claim 13, wherein the composition is a topical composition. 15. The method of claim 14, wherein the histone hyperacetylating agent is sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, propionate, butyramide, isobutyramide, phenylacetate, 3-bromopropionate, valproic acid, valproate, or tributyrin. 16. The method of claim 15, wherein the histone hyperacetylating agent is sodium 4-phenylbutyrate. 17. The method of claim 1, wherein the skin disorder is pityriasis rosea. 18. The method of claim 1, wherein the skin disorder is erythema. 19. The method of claim 1, wherein the skin disorder is rhinophyma. |
Details for Patent 8,492,438
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | 06/04/1965 | ⤷ Try a Trial | 2022-04-26 |
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2022-04-26 |
Auxilium Pharmaceuticals, Inc. | XIAFLEX | collagenase clostridium histolyticum | For Injection | 125338 | 02/02/2010 | ⤷ Try a Trial | 2022-04-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.